Limitations of the C6/Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy
Intracranial rat glioma models are a useful method for evaluating the efficacy and toxicity of novel therapies for malignant glioma. The C6/Wistar model has been used extensively as a reproducible in vivo model for studying primary brain tumors including anti-glioma immune responses. The objective o...
Gespeichert in:
| Veröffentlicht in: | Neurosurgery 2000-10, Vol.47 (4), p.993-1000 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1000 |
|---|---|
| container_issue | 4 |
| container_start_page | 993 |
| container_title | Neurosurgery |
| container_volume | 47 |
| creator | PARSA, Andrew T CHAKRABARTI, Indro LICHTOR, Terry BLACK, Peter Mcl HURLEY, Patrick T CHI, John H HALL, Jonathan S KAISER, Michael G BRUCE, Jeffrey N ROCK, Jack P PIEPMEIER, Joseph M GLICK, Roberta P |
| description | Intracranial rat glioma models are a useful method for evaluating the efficacy and toxicity of novel therapies for malignant glioma. The C6/Wistar model has been used extensively as a reproducible in vivo model for studying primary brain tumors including anti-glioma immune responses. The objective of the present study is to provide in vivo evidence that the C6 rat glioma model is allogeneic within Wistar rats and is therefore inappropriate for evaluating immune responses.
Growth patterns and immune responses of C6 cells implanted into the brain and flank of Wistar rats were analyzed and compared to an immunogenic syngeneic model (9L/Fischer).
Wistar rats with C6 tumors developed a potent humoral and cellular immune response to the tumor. Wistar rats given simultaneous flank and intracerebral tumors had a survival rate of 100% compared to an 11% survival rate in control animals receiving only intracranial C6 cells.
The C6 rat glioma induces a vigorous immune reaction that may mimic a specific anti-tumor response in Wistar rats. Efficacy of immunotherapy within this model must be cautiously interpreted. |
| doi_str_mv | 10.1097/00006123-200010000-00050 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00006123_200010000_00050</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>11014444</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-f2b3fb08474ae1872c47d1bede9e3c18d5cb6d8d094c8094652342fb91dc8be93</originalsourceid><addsrcrecordid>eNpFkF1LwzAUhoMobk7_guTC27ikTdvUOxl-DAbeKHpX8jkjTVuSVNi_N3PVHUhODnnec_EAAAm-JbiuljhVSbIcZelB9hNKp8AnYE6KjCKKKT4Fc0woQ3ldfszARQhfCS1pxc7BjJD0lWoOzMY6G3m0fRdgb2D81HBVLt9tiNxDzyO0XfRcaq-F5y3ctrZ3HLpe6fYOrt3QWjmlTe-h_ubtmOZuC61zY9enfZ4Pu0twZngb9NXUF-Dt8eF19Yw2L0_r1f0GSYrLiEwmciMwoxXlmrAqk7RSRGila51LwlQhRamYwjWVLF1lkeU0M6ImSjKh63wB2GGv9H0IXptm8NZxv2sIbvbqmj91zb-65lddil4fosMonFbH4OQqATcTwIPkrfG8kzYcuSKRRZX_AMHDd94</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Limitations of the C6/Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>PARSA, Andrew T ; CHAKRABARTI, Indro ; LICHTOR, Terry ; BLACK, Peter Mcl ; HURLEY, Patrick T ; CHI, John H ; HALL, Jonathan S ; KAISER, Michael G ; BRUCE, Jeffrey N ; ROCK, Jack P ; PIEPMEIER, Joseph M ; GLICK, Roberta P</creator><creatorcontrib>PARSA, Andrew T ; CHAKRABARTI, Indro ; LICHTOR, Terry ; BLACK, Peter Mcl ; HURLEY, Patrick T ; CHI, John H ; HALL, Jonathan S ; KAISER, Michael G ; BRUCE, Jeffrey N ; ROCK, Jack P ; PIEPMEIER, Joseph M ; GLICK, Roberta P</creatorcontrib><description>Intracranial rat glioma models are a useful method for evaluating the efficacy and toxicity of novel therapies for malignant glioma. The C6/Wistar model has been used extensively as a reproducible in vivo model for studying primary brain tumors including anti-glioma immune responses. The objective of the present study is to provide in vivo evidence that the C6 rat glioma model is allogeneic within Wistar rats and is therefore inappropriate for evaluating immune responses.
Growth patterns and immune responses of C6 cells implanted into the brain and flank of Wistar rats were analyzed and compared to an immunogenic syngeneic model (9L/Fischer).
Wistar rats with C6 tumors developed a potent humoral and cellular immune response to the tumor. Wistar rats given simultaneous flank and intracerebral tumors had a survival rate of 100% compared to an 11% survival rate in control animals receiving only intracranial C6 cells.
The C6 rat glioma induces a vigorous immune reaction that may mimic a specific anti-tumor response in Wistar rats. Efficacy of immunotherapy within this model must be cautiously interpreted.</description><identifier>ISSN: 0148-396X</identifier><identifier>EISSN: 1524-4040</identifier><identifier>DOI: 10.1097/00006123-200010000-00050</identifier><identifier>PMID: 11014444</identifier><identifier>CODEN: NRSRDY</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Animals ; Antibody Formation ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Brain Neoplasms - immunology ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Brain Neoplasms - therapy ; Cell Division ; Glioma - immunology ; Glioma - metabolism ; Glioma - pathology ; Glioma - therapy ; Immunity, Cellular ; Immunotherapy - standards ; Male ; Medical sciences ; Neoplasm Transplantation ; Neurology ; Rats ; Rats, Inbred F344 - immunology ; Rats, Wistar - immunology ; Survival Analysis ; Topotecan - administration & dosage ; Topotecan - therapeutic use ; Tumor Cells, Cultured ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Neurosurgery, 2000-10, Vol.47 (4), p.993-1000</ispartof><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-f2b3fb08474ae1872c47d1bede9e3c18d5cb6d8d094c8094652342fb91dc8be93</citedby><cites>FETCH-LOGICAL-c406t-f2b3fb08474ae1872c47d1bede9e3c18d5cb6d8d094c8094652342fb91dc8be93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1511057$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11014444$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PARSA, Andrew T</creatorcontrib><creatorcontrib>CHAKRABARTI, Indro</creatorcontrib><creatorcontrib>LICHTOR, Terry</creatorcontrib><creatorcontrib>BLACK, Peter Mcl</creatorcontrib><creatorcontrib>HURLEY, Patrick T</creatorcontrib><creatorcontrib>CHI, John H</creatorcontrib><creatorcontrib>HALL, Jonathan S</creatorcontrib><creatorcontrib>KAISER, Michael G</creatorcontrib><creatorcontrib>BRUCE, Jeffrey N</creatorcontrib><creatorcontrib>ROCK, Jack P</creatorcontrib><creatorcontrib>PIEPMEIER, Joseph M</creatorcontrib><creatorcontrib>GLICK, Roberta P</creatorcontrib><title>Limitations of the C6/Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy</title><title>Neurosurgery</title><addtitle>Neurosurgery</addtitle><description>Intracranial rat glioma models are a useful method for evaluating the efficacy and toxicity of novel therapies for malignant glioma. The C6/Wistar model has been used extensively as a reproducible in vivo model for studying primary brain tumors including anti-glioma immune responses. The objective of the present study is to provide in vivo evidence that the C6 rat glioma model is allogeneic within Wistar rats and is therefore inappropriate for evaluating immune responses.
Growth patterns and immune responses of C6 cells implanted into the brain and flank of Wistar rats were analyzed and compared to an immunogenic syngeneic model (9L/Fischer).
Wistar rats with C6 tumors developed a potent humoral and cellular immune response to the tumor. Wistar rats given simultaneous flank and intracerebral tumors had a survival rate of 100% compared to an 11% survival rate in control animals receiving only intracranial C6 cells.
The C6 rat glioma induces a vigorous immune reaction that may mimic a specific anti-tumor response in Wistar rats. Efficacy of immunotherapy within this model must be cautiously interpreted.</description><subject>Animals</subject><subject>Antibody Formation</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Brain Neoplasms - immunology</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Brain Neoplasms - therapy</subject><subject>Cell Division</subject><subject>Glioma - immunology</subject><subject>Glioma - metabolism</subject><subject>Glioma - pathology</subject><subject>Glioma - therapy</subject><subject>Immunity, Cellular</subject><subject>Immunotherapy - standards</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neoplasm Transplantation</subject><subject>Neurology</subject><subject>Rats</subject><subject>Rats, Inbred F344 - immunology</subject><subject>Rats, Wistar - immunology</subject><subject>Survival Analysis</subject><subject>Topotecan - administration & dosage</subject><subject>Topotecan - therapeutic use</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0148-396X</issn><issn>1524-4040</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkF1LwzAUhoMobk7_guTC27ikTdvUOxl-DAbeKHpX8jkjTVuSVNi_N3PVHUhODnnec_EAAAm-JbiuljhVSbIcZelB9hNKp8AnYE6KjCKKKT4Fc0woQ3ldfszARQhfCS1pxc7BjJD0lWoOzMY6G3m0fRdgb2D81HBVLt9tiNxDzyO0XfRcaq-F5y3ctrZ3HLpe6fYOrt3QWjmlTe-h_ubtmOZuC61zY9enfZ4Pu0twZngb9NXUF-Dt8eF19Yw2L0_r1f0GSYrLiEwmciMwoxXlmrAqk7RSRGila51LwlQhRamYwjWVLF1lkeU0M6ImSjKh63wB2GGv9H0IXptm8NZxv2sIbvbqmj91zb-65lddil4fosMonFbH4OQqATcTwIPkrfG8kzYcuSKRRZX_AMHDd94</recordid><startdate>20001001</startdate><enddate>20001001</enddate><creator>PARSA, Andrew T</creator><creator>CHAKRABARTI, Indro</creator><creator>LICHTOR, Terry</creator><creator>BLACK, Peter Mcl</creator><creator>HURLEY, Patrick T</creator><creator>CHI, John H</creator><creator>HALL, Jonathan S</creator><creator>KAISER, Michael G</creator><creator>BRUCE, Jeffrey N</creator><creator>ROCK, Jack P</creator><creator>PIEPMEIER, Joseph M</creator><creator>GLICK, Roberta P</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20001001</creationdate><title>Limitations of the C6/Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy</title><author>PARSA, Andrew T ; CHAKRABARTI, Indro ; LICHTOR, Terry ; BLACK, Peter Mcl ; HURLEY, Patrick T ; CHI, John H ; HALL, Jonathan S ; KAISER, Michael G ; BRUCE, Jeffrey N ; ROCK, Jack P ; PIEPMEIER, Joseph M ; GLICK, Roberta P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-f2b3fb08474ae1872c47d1bede9e3c18d5cb6d8d094c8094652342fb91dc8be93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Antibody Formation</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Brain Neoplasms - immunology</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Brain Neoplasms - therapy</topic><topic>Cell Division</topic><topic>Glioma - immunology</topic><topic>Glioma - metabolism</topic><topic>Glioma - pathology</topic><topic>Glioma - therapy</topic><topic>Immunity, Cellular</topic><topic>Immunotherapy - standards</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neoplasm Transplantation</topic><topic>Neurology</topic><topic>Rats</topic><topic>Rats, Inbred F344 - immunology</topic><topic>Rats, Wistar - immunology</topic><topic>Survival Analysis</topic><topic>Topotecan - administration & dosage</topic><topic>Topotecan - therapeutic use</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PARSA, Andrew T</creatorcontrib><creatorcontrib>CHAKRABARTI, Indro</creatorcontrib><creatorcontrib>LICHTOR, Terry</creatorcontrib><creatorcontrib>BLACK, Peter Mcl</creatorcontrib><creatorcontrib>HURLEY, Patrick T</creatorcontrib><creatorcontrib>CHI, John H</creatorcontrib><creatorcontrib>HALL, Jonathan S</creatorcontrib><creatorcontrib>KAISER, Michael G</creatorcontrib><creatorcontrib>BRUCE, Jeffrey N</creatorcontrib><creatorcontrib>ROCK, Jack P</creatorcontrib><creatorcontrib>PIEPMEIER, Joseph M</creatorcontrib><creatorcontrib>GLICK, Roberta P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PARSA, Andrew T</au><au>CHAKRABARTI, Indro</au><au>LICHTOR, Terry</au><au>BLACK, Peter Mcl</au><au>HURLEY, Patrick T</au><au>CHI, John H</au><au>HALL, Jonathan S</au><au>KAISER, Michael G</au><au>BRUCE, Jeffrey N</au><au>ROCK, Jack P</au><au>PIEPMEIER, Joseph M</au><au>GLICK, Roberta P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limitations of the C6/Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy</atitle><jtitle>Neurosurgery</jtitle><addtitle>Neurosurgery</addtitle><date>2000-10-01</date><risdate>2000</risdate><volume>47</volume><issue>4</issue><spage>993</spage><epage>1000</epage><pages>993-1000</pages><issn>0148-396X</issn><eissn>1524-4040</eissn><coden>NRSRDY</coden><abstract>Intracranial rat glioma models are a useful method for evaluating the efficacy and toxicity of novel therapies for malignant glioma. The C6/Wistar model has been used extensively as a reproducible in vivo model for studying primary brain tumors including anti-glioma immune responses. The objective of the present study is to provide in vivo evidence that the C6 rat glioma model is allogeneic within Wistar rats and is therefore inappropriate for evaluating immune responses.
Growth patterns and immune responses of C6 cells implanted into the brain and flank of Wistar rats were analyzed and compared to an immunogenic syngeneic model (9L/Fischer).
Wistar rats with C6 tumors developed a potent humoral and cellular immune response to the tumor. Wistar rats given simultaneous flank and intracerebral tumors had a survival rate of 100% compared to an 11% survival rate in control animals receiving only intracranial C6 cells.
The C6 rat glioma induces a vigorous immune reaction that may mimic a specific anti-tumor response in Wistar rats. Efficacy of immunotherapy within this model must be cautiously interpreted.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>11014444</pmid><doi>10.1097/00006123-200010000-00050</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0148-396X |
| ispartof | Neurosurgery, 2000-10, Vol.47 (4), p.993-1000 |
| issn | 0148-396X 1524-4040 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00006123_200010000_00050 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Animals Antibody Formation Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use Biological and medical sciences Brain Neoplasms - immunology Brain Neoplasms - metabolism Brain Neoplasms - pathology Brain Neoplasms - therapy Cell Division Glioma - immunology Glioma - metabolism Glioma - pathology Glioma - therapy Immunity, Cellular Immunotherapy - standards Male Medical sciences Neoplasm Transplantation Neurology Rats Rats, Inbred F344 - immunology Rats, Wistar - immunology Survival Analysis Topotecan - administration & dosage Topotecan - therapeutic use Tumor Cells, Cultured Tumors of the nervous system. Phacomatoses |
| title | Limitations of the C6/Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A29%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limitations%20of%20the%20C6/Wistar%20rat%20intracerebral%20glioma%20model:%20Implications%20for%20evaluating%20immunotherapy&rft.jtitle=Neurosurgery&rft.au=PARSA,%20Andrew%20T&rft.date=2000-10-01&rft.volume=47&rft.issue=4&rft.spage=993&rft.epage=1000&rft.pages=993-1000&rft.issn=0148-396X&rft.eissn=1524-4040&rft.coden=NRSRDY&rft_id=info:doi/10.1097/00006123-200010000-00050&rft_dat=%3Cpubmed_cross%3E11014444%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/11014444&rfr_iscdi=true |